Q-omics provides the consensus-scored KHDRBS3 profile across patient tissues and cancer cell-line models. KHDRBS3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KHDRBS3 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, KHDRBS3 protein abundance shows 21,455 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRP, and GBM as cancer lineages where KHDRBS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KHDRBS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KHDRBS3 survival associations across molecular data types. KHDRBS3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KHDRBS3 RNA expression–survival associations across cancer types. High KHDRBS3 expression shows unfavorable associations in UVM, ACC and LIHC, but favorable associations in KIRC, SKCM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KHDRBS3 RNA expression.
This table summarizes KHDRBS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KHDRBS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KHDRBS3 shows lower tumor expression in BRCA and BLCA and higher tumor expression in KIRP, COAD, LIHC and READ. The KIRP box plot shows higher KHDRBS3 RNA expression in tumor versus normal tissue (log2 FC = +0.964, t-test p < 0.001).
This table shows molecular features associated with KHDRBS3 in patient tissues and cancer cell lines. In patient samples, KHDRBS3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KHDRBS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
